WO1999062893A3 - Neue neurokininantagonisten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen - Google Patents

Neue neurokininantagonisten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen Download PDF

Info

Publication number
WO1999062893A3
WO1999062893A3 PCT/EP1999/003531 EP9903531W WO9962893A3 WO 1999062893 A3 WO1999062893 A3 WO 1999062893A3 EP 9903531 W EP9903531 W EP 9903531W WO 9962893 A3 WO9962893 A3 WO 9962893A3
Authority
WO
WIPO (PCT)
Prior art keywords
production
compounds
pharmaceutical compositions
compositions containing
neurokinin antagonists
Prior art date
Application number
PCT/EP1999/003531
Other languages
English (en)
French (fr)
Other versions
WO1999062893A2 (de
Inventor
Franz Esser
Gerd Schnorrenberg
Horst Dollinger
Sven Luettke
Birgit Jung
Georg Speck
Original Assignee
Boehringer Ingelheim Pharma
Franz Esser
Gerd Schnorrenberg
Horst Dollinger
Sven Luettke
Birgit Jung
Georg Speck
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Pharma, Franz Esser, Gerd Schnorrenberg, Horst Dollinger, Sven Luettke, Birgit Jung, Georg Speck filed Critical Boehringer Ingelheim Pharma
Priority to EP99926368A priority Critical patent/EP1086088A2/de
Priority to JP2000552105A priority patent/JP2002517386A/ja
Priority to CA002333689A priority patent/CA2333689A1/en
Publication of WO1999062893A2 publication Critical patent/WO1999062893A2/de
Publication of WO1999062893A3 publication Critical patent/WO1999062893A3/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D295/00—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms
    • C07D295/16—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms
    • C07D295/20—Heterocyclic compounds containing polymethylene-imine rings with at least five ring members, 3-azabicyclo [3.2.2] nonane, piperazine, morpholine or thiomorpholine rings, having only hydrogen atoms directly attached to the ring carbon atoms acylated on ring nitrogen atoms by radicals derived from carbonic acid, or sulfur or nitrogen analogues thereof
    • C07D295/215—Radicals derived from nitrogen analogues of carbonic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
    • C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D233/28—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D233/44—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/06—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D239/08—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms directly attached in position 2
    • C07D239/12—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Die Erfindung betrifft neue Verbindungen der allgemeinen Formel (I) oder deren pharmazeutisch annehmbare Salze, worin X = N-R3 oder CH-R4 ist, Y = CH¿2? oder (CH2)2 ist, Z = O oder H2 bedeutet; und R?1, R2, R3, R4¿ und Ar die in der Beschreibung angegebenen Bedeutungen besitzen sowie deren Herstellung und Verwendung. Die neuen Verbindungen sind wertvolle Neurokinin (Tachykinin)-Antagonisten.
PCT/EP1999/003531 1998-05-30 1999-05-22 Neue neurokininantagonisten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen WO1999062893A2 (de)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP99926368A EP1086088A2 (de) 1998-05-30 1999-05-22 Neue neurokininantagonisten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
JP2000552105A JP2002517386A (ja) 1998-05-30 1999-05-22 新規なニューロキニン拮抗物質、その調製方法及びその化合物を含む医薬組成物
CA002333689A CA2333689A1 (en) 1998-05-30 1999-05-22 New neurokinin antagonists, processes for preparing them and pharmaceutical compositions containing said compounds

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19824470A DE19824470A1 (de) 1998-05-30 1998-05-30 Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
DE19824470.3 1998-05-30

Publications (2)

Publication Number Publication Date
WO1999062893A2 WO1999062893A2 (de) 1999-12-09
WO1999062893A3 true WO1999062893A3 (de) 2000-03-09

Family

ID=7869575

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/EP1999/003531 WO1999062893A2 (de) 1998-05-30 1999-05-22 Neue neurokininantagonisten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen

Country Status (6)

Country Link
US (5) US6103719A (de)
EP (1) EP1086088A2 (de)
JP (1) JP2002517386A (de)
CA (1) CA2333689A1 (de)
DE (1) DE19824470A1 (de)
WO (1) WO1999062893A2 (de)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6413959B1 (en) 1995-04-14 2002-07-02 Boehringer Ingelheim Kg Method of treating depression with arylglycinamide derivatives
US6291514B1 (en) * 1998-02-09 2001-09-18 3-Dimensional Pharmaceuticals, Inc. Heteroaryl amidines, methylamidines and guanidines, preparation thereof, and use thereof as protease inhibitors
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US6875759B1 (en) 1999-07-21 2005-04-05 Kadmus Pharmaceuticals Substituted guanidines and the use thereof
DE60129562T2 (de) * 2000-06-12 2008-04-17 The University Of Rochester Methode zur Behandlung von Hitzewallungen durch Verwendung eines Tachykinin-Rezeptor-Antagonisten
UA75093C2 (en) 2000-10-06 2006-03-15 Dimensional Pharm Inc Aminopyridinyl-,aminoguanidinyl-, and alkoxyguanidinesubstituted phenylsubstituted phenylacetamides as protease inhibitors
NZ544715A (en) * 2003-08-18 2009-09-25 Lundbeck & Co As H Succinate and malonate salt of trans-4-((1R,3S)-6-chloro-3-phenylindan-1-yl)-1,2,2-trimethylpiperazine and the use as a medicament
JP2007532638A (ja) * 2004-04-14 2007-11-15 アストラゼネカ・アクチエボラーグ Ｎｋ１アンタゴニスト及びセロトニン再取り込み阻害剤としてのアリールグリシンアミド誘導体及びその使用
TWI376373B (en) 2005-02-16 2012-11-11 Lundbeck & Co As H Crystalline base of a pharmaceutical compound
TWI453198B (zh) * 2005-02-16 2014-09-21 Lundbeck & Co As H 製造反式-1-((1r,3s)-6-氯基-3-苯基茚滿-1-基) -3 , 3 -二甲基六氫吡與其鹽類之方法及製造4-((1r , 3s）-6 -氯基-3-苯基茚滿-1-基 )-1,2,2-三甲基六氫吡與其鹽類之方法
WO2008090114A1 (en) 2007-01-24 2008-07-31 Glaxo Group Limited Pharmaceutical compositions comprising 2-methoxy-5- (5-trifluoromethyl-tetrazol-i-yl-benzyl) - (2s-phenyl-piperidin-3s-yl-)
EA018927B1 (ru) * 2008-05-07 2013-11-29 Х. Лундбекк А/С Способ лечения когнитивного расстройства, ассоциированного с шизофренией
DE102015104299A1 (de) * 2015-03-23 2016-09-29 International Automotive Components Group Gmbh Innenverkleidungsteil für ein Kraftfahrzeug
ES2912276T3 (es) * 2015-04-07 2022-05-25 Ela Pharma Ltd Composiciones para tratar y/o prevenir necrosis celular o tisular que seleccionan como diana específicamente catepsina C y/o CELA1 y/o CELA3A y/o enzimas estructuralmente relacionadas con las mismas

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19608665A1 (de) * 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA1173037A (en) * 1980-03-01 1984-08-21 John L. Archibald Piperidino ureas as antidepressants
US5364943A (en) * 1991-11-27 1994-11-15 Pfizer Inc. Preparation of substituted piperidines
TW201303B (de) * 1990-07-05 1993-03-01 Hoffmann La Roche
US5607936A (en) * 1994-09-30 1997-03-04 Merck & Co., Inc. Substituted aryl piperazines as neurokinin antagonists
TW449590B (en) * 1995-04-14 2001-08-11 Boehringer Ingelheim Kg New arylglycinamide derivatives, processes for the manufacture thereof and pharmaceutical compositions containing these compounds
DE19519245C2 (de) * 1995-04-14 2003-04-30 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen
US5795894A (en) * 1995-05-02 1998-08-18 Schering Corporation Piperazino derivatives as neurokinn antagonists
US5654316A (en) * 1995-06-06 1997-08-05 Schering Corporation Piperidine derivatives as neurokinin antagonists
DE19824470A1 (de) * 1998-05-30 1999-12-02 Boehringer Ingelheim Pharma Neue Neurokininantagonisten, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE19608665A1 (de) * 1996-03-06 1997-09-11 Boehringer Ingelheim Kg Neue Arylglycinamidderivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende pharmazeutische Zusammensetzungen

Also Published As

Publication number Publication date
EP1086088A2 (de) 2001-03-28
DE19824470A1 (de) 1999-12-02
US6103719A (en) 2000-08-15
US20020133012A1 (en) 2002-09-19
CA2333689A1 (en) 1999-12-09
US20020010173A1 (en) 2002-01-24
US6455700B1 (en) 2002-09-24
US6277840B1 (en) 2001-08-21
US20020147359A1 (en) 2002-10-10
US6429328B2 (en) 2002-08-06
WO1999062893A2 (de) 1999-12-09
JP2002517386A (ja) 2002-06-18

Similar Documents

Publication Publication Date Title
IL111960A (en) Morpholines and thiomorpholines their preparation and pharmaceutical compositions containing them
CA2067877A1 (en) Polycyclic amine compounds and their enantiomers, their method of preparation and pharmaceutical compositions in which they are present
WO2002098856A3 (en) Piperazine oxyquinoline (naphthaline) platelet adenosine diphosphate receptor antagonists
MX9803004A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
MX9701955A (es) Antagonistas de neuroquinina.
WO1999062893A3 (de) Neue neurokininantagonisten, verfahren zu ihrer herstellung und diese verbindungen enthaltende pharmazeutische zusammensetzungen
CA2318349A1 (en) Estrone sulfamate inhibitors of estrone sulfatase, and associated pharmaceutical compositions and methods of use
BG100946A (en) New amino acid derivatives, method for their preparation and pharmaceutical compositions containing them
IL106900A0 (en) Amino acid derivatives,their manufacture and pharmaceutical compositions containing them
PL344012A1 (en) Novel substituted cyclic compounds, preparation method and pharmaceutical compositions containing them
BG103485A (en) Ketobanzamides as calpain inhibitors
MX9707053A (es) Nuevos derivados de arilglicinamida, procedimiento para su preparacion, y composiciones farmaceuticas que contienen estos compuestos.
CA2337825A1 (en) Disubstituted bicyclic heterocycles, the preparation thereof and their use as pharmaceutical compositions
YU30902A (sh) Novi ciklopropani kao cgrp antagonisti, lekovi koji sadrže navedena jedinjenja i postupak za njihovu proizvodnju
NZ332201A (en) Novel aryl glycinamide derivatives, method of producing said derivatives and pharmaceutical compositions containing these compounds
MY133445A (en) 2-arylethyl-(piperidin-4-ylmethyl)amine derivetives
EP2394992A3 (de) Substituierte Piperidinverbindungen und Verfahren zu deren Verwendung
AU1442297A (en) Piperidone tachykinin antagonists
MX9603272A (es) Nuevos derivados de aminoacidos, procedimiento para su preparacion y composiciones farmaceuticas que contienen estos compuestos.
PL315052A1 (en) Condensed dihydropyridines, method of obtaining them, their application in producing pharmaceutic preparations and pharmaceutic preparations containing such compounds
WO2001010861A3 (de) Substituierte heterocyclyl-2h-chromene
CA2426221A1 (en) New neurokinin antagonists, processes for preparing them and pharmaceutical compositions containing these compounds
CA2425164A1 (en) (4-acylaminopiperidin-1-yl)acetamides as neurokinin antagonists
TW336224B (en) Compound useful as adhesion receptor antagonists, their preparation processes, and pharmaceutical compositions containing same
ES8402287A1 (es) Procedimiento de obtencion de nuevas carboxamidoguanidinas.

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE

WWE Wipo information: entry into national phase

Ref document number: PA/a/2000/011731

Country of ref document: MX

ENP Entry into the national phase

Ref document number: 2333689

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1999926368

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1999926368

Country of ref document: EP

NENP Non-entry into the national phase

Ref country code: CA

WWW Wipo information: withdrawn in national office

Ref document number: 1999926368

Country of ref document: EP